PDGFRA and central nervous system cancer: Avapritinib demonstrates CNS penetrance in preclinical models with steady-state brain-to-plasma ratios ranging 0.74–1.0032, and exhibits clinical activity in PDGFRA-altered high-grade glioma patients33.